Back

Plasma cytokines are associated with major adverse cardiovascular events in follow-up of patients undergoing carotid endarterectomy

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Carotid plaque: epidemiology and evolution Carotid Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Valentina Nardi

Mayo Clinic, Rochester (United States of America)

6 More presentations in this session

Presentation thumbnail
Adverse outcomes following carotid artery stenting in echolucent plaques: a systematic review and meta-analysis
Associate Professor P. Ibrahimi (Pristina, XK)
Abstract Slides Video
Presentation thumbnail
Plasma levels of sCASP3 predicts carotid intima media thickness progression
Miss M. Pan (Malmo, SE)
Abstract Slides Video
Presentation thumbnail
Mortality risk in patients with carotid artery disease undergoing carotid endarterectomy compared to the general population
Doctor L. Di Venanzio (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Minimal extra-cardiac atherosclerosis in people <50 years with sudden cardiac death due to coronary disease
Doctor E. Paratz (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Effect of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on carotid intima-media thickness
Doctor K. Katogiannis (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Carotid plaque: epidemiology and evolution

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Intraplaque hemorrhage in carotid atherosclerotic plaques is associated with a local increase in inflammatory cytokines
thumbnail
Congress Presentation
Leukocyte trajectories and cardiovascular events in individuals with and without carotid plaque: a community cohort study
thumbnail
Congress Presentation
Inflammation and LDL cholesterol contribute independently to the progression of early human atherosclerotic plaque

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources